Thiols as a marker of inflammatory bowel disease activity: a systematic review

• Published in: BMC gastroenterology 2023-03, Vol.23 (1), p.94-15, Article 94
• Main Authors: Passos, Rebeca Araujo, Costa, Priscila Ribas Farias, da Maia Lima, Claudia Feio, Santana, George Mariane Soares, David, Victor, de Jesus Santos, Geisa, Zaltman, Cyrla, Soares-Mota, Marcia, Rocha, Raquel
• Format: Article
• Language: English
• Subjects: Analysis; Biological markers; Biomarkers; Care and treatment; Chronic illnesses; Colitis, Ulcerative - complications; Crohn Disease - complications; Crohn's Disease; Diagnosis; Endoscopy; Gastroenterology; Humans; Inflammation; Inflammatory Bowel Disease; Inflammatory bowel diseases; Inflammatory Bowel Diseases - complications; Inflammatory Bowel Diseases - diagnosis; Intestine; Meta-analysis; Oxidative stress; Phenotypes; Plasma; Reactive oxygen species; Remission (Medicine); Reviews; Software; Standardization; Sulfhydryl Compounds; Symptomatology; Systematic Review; Thiols; Ulcerative Colitis; Vocabularies & taxonomies
• ISSN: 1471-230X; 1471-230X
• DOI: 10.1186/s12876-023-02711-9

Evidence indicates that inflammation in Inflammatory Bowel Disease (IBD) is associated with increased systemic levels of reactive oxygen species. Systemic oxidative stress has been associated with reduced levels of plasma thiols. Less invasive tests capable of reflecting and predicting IBD activity are increasingly sought after. We sought to systematically review the evidence inherent in serum thiol levels as a marker of Crohn's Disease and Ulcerative Colitis activity (PROSPERO: CRD42021255521). The highest quality documents for systematic reviews standards were used as reference. Articles were searched on Medline via PubMed, VHL, LILACS, WOS, EMBASE, SCOPUS, COCHRANE, CINAHL, OVID, CTGOV, WHO/ICTRP, OPENGREY, BDTD and CAPES, between August, 03 and September, 03 on 2021. Descriptors were defined according to the Medical Subject Heading. Of the 11 articles selected for full reading, 8 were included in the review. It was not possible to perform a pooled analysis of the studies, as there were no combinable studies between subjects with active IBD and controls/inactive disease. Findings from the individual studies included in this review suggest an association between disease activity and systemic oxidation, as measured by serum thiol levels, however, there are limitations that preclude weighting the study results in a meta-analysis. We recommend conducting better-designed and controlled studies, that include individuals of both phenotypes and at different stages of IBD, involving a larger number of participants, using the standardization of the technique for measuring serum thiols, to confirm whether thiols can be a good parameter for monitoring the clinical course of these intestinal diseases and the degree of clinical applicability.